坦桑尼亚采用单剂或两剂策略交付人乳头瘤病毒疫苗接种的成本
本研究基于DoRIS试验,采用WHO的C4P微成本核算工具,从坦桑尼亚政府视角估算全国HPV疫苗接种项目的财务与经济成本。结果显示两剂策略每名完全免疫女孩的财务成本为5.17美元、经济成本为23.34美元,单剂策略分别降至2.51美元和12.18美元。作者认为该成本低于该地区以往示范项目,可为坦桑尼亚及尚未引入HPV疫苗的国家提供基线数据。
要点
- 两剂策略每名完全免疫女孩财务成本5.17美元、经济成本23.34美元。
- 单剂策略每名完全免疫女孩财务成本降至2.51美元、经济成本降至12.18美元。
- 疫苗及疫苗相关成本占比最大,其次为服务提供。
核心结论
- 坦桑尼亚HPV疫苗接种项目每名接种者的总体成本低于该地区以往示范项目估算的成本,单剂策略下尤其低。
- 鉴于WHO免疫战略咨询专家组近期建议将HPV疫苗接种程序更新为一剂或两剂,这些数据为坦桑尼亚提供了重要基线数据,并可能作为今后提高覆盖率的指南。
- 研究结果还可能有助于尚未将HPV疫苗纳入常规免疫的国家优先安排资金。
研究设计与样本
- 本研究是DoRIS试验(NCT02834637)的一部分,采用WHO宫颈癌预防与控制成本核算(C4P)微成本核算工具,从坦桑尼亚政府视角估算全国疫苗接种项目的总财务成本和经济成本。
- 成本数据于2019年通过问卷调查、研讨会和与当地利益相关者的访谈收集,涵盖疫苗和注射用品、微观规划、培训、宣传动员、服务提供、监督和冷链。
- 计算了每名两剂和单剂完全免疫女孩(FIG)的成本。
主要发现
- 总财务成本为10,117,455美元,总经济成本为45,683,204美元。
- 两剂策略每名完全免疫女孩的财务成本为5.17美元,经济成本为23.34美元。
- 单剂策略每名完全免疫女孩的财务成本降至2.51美元,经济成本降至12.18美元,其中疫苗和注射用品成本及服务提供成本降幅最大。
- 疫苗和疫苗相关成本占成本比例最大,其次为服务提供。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As part of the Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls (DoRIS; NCT02834637), the current study is one of the first to evaluate the financial and economic costs of the national rollout of an HPV vaccination program in school-aged girls in sub-Saharan Africa and the potential costs associated with a single dose HPV vaccine program, given recent evidence suggesting that a single dose may be as efficacious as a two-dose regimen. METHODS: The World Health Organization's (WHO) Cervical Cancer Prevention and Control Costing (C4P) micro-costing tool was used to estimate the total financial and economic costs of the national vaccination program from the perspective of the Tanzanian government. Cost data were collected in 2019 via surveys, workshops, and interviews with local stakeholders for vaccines and injection supplies, microplanning, training, sensitization, service delivery, supervision, and cold chain. The cost per two-dose and one-dose fully immunized girl (FIG) was calculated. RESULTS: The total financial and economic costs were US$10,117,455 and US$45,683,204, respectively, at a financial cost of $5.17 per two-dose FIG, and an economic cost of $23.34 per FIG. Vaccine and vaccine-related costs comprised the largest proportion of costs, followed by service delivery. In a one-dose scenario, the cost per FIG reduced to $2.51 (financial) and $12.18 (economic), with the largest reductions in vaccine and injection supply costs, and service delivery. CONCLUSIONS: The overall cost of Tanzania's HPV vaccination program was lower per vaccinee than costs estimated from previous demonstration projects in the region, especially in a single-dose scenario. Given the WHO Strategic Advisory Group of Experts on Immunization's recent recommendation to update dosing schedules to either one or two doses of the HPV vaccine, these data provide important baseline data for Tanzania and may serve as a guide for improving coverage going forward. The findings may also aid in the prioritization of funding for countries that have not yet added HPV vaccines to their routine immunizations.
引用
- Hsiao A, Struckmann V, Stephani V, et al. Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania. Vaccine. 2022. PMID: 36460537. doi:10.1016/j.vaccine.2022.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。